car t therapy, impact car t therapy, car t impact, health care, cancer treatment

E02 — CAR-T Cell Therapy: A $100B Opportunity for Personalized Cancer Care

ARK Disrupt Podcast is designed to keep you engaged with the most disruptive innovations evolving today. Our second episode features Manisha Samy, Health Care and Genomics Analyst at ARK Invest. James Wang and Manisha chat about innovations in health care and how CAR-T cell therapy could be revolutionary for cancer treatment.

ARK's statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, click here.

1 reply
  1. Jason Dilks says:

    The one company ( with the best switch ) might be Intrexon. Too soon to see but their Aquisition of GenVec might turn out to be one of the best delivery modes. I enjoyed your podcast and keep up the great research !


Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *